Alumis (ALMS) – Analysts’ Weekly Ratings Updates

Several brokerages have updated their recommendations and price targets on shares of Alumis (NASDAQ: ALMS) in the last few weeks:

  • 11/16/2026 – Alumis had its price target lowered by Oppenheimer to $28.00. They now have an “outperform” rating on the stock.
  • 11/13/2026 – Alumis was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
  • 11/13/2026 – Alumis had its price target lowered by Wells Fargo & Company from $25.00 to $18.00. They now have an “overweight” rating on the stock.
  • 11/13/2026 – Alumis had its price target lowered by HC Wainwright from $15.00 to $9.00. They now have a “buy” rating on the stock.
  • 10/27/2026 – Alumis was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
  • 10/5/2026 – Alumis had its “buy” rating reaffirmed by Benchmark.
  • 10/5/2026 – Alumis had its “buy” rating reaffirmed by HC Wainwright.
  • 10/2/2026 – Alumis had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Alumis Price Performance

Alumis stock opened at $5.14 on Tuesday. The stock’s fifty day moving average price is $7.12 and its two-hundred day moving average price is $20.35. Alumis Inc. has a one year low of $5.00 and a one year high of $31.35. The firm has a market cap of $665.27 million, a PE ratio of -1.46 and a beta of -0.28.

Alumis (NASDAQ:ALMS – Get Free Report) last released its earnings results on Thursday, November 12th. The company reported ($0.73) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.03. The firm had revenue of $1.91 million during the quarter, compared to the consensus estimate of $1.90 million. Alumis had a negative return on equity of 86.62% and a negative net margin of 5,844.54%. Sell-side analysts expect that Alumis Inc. will post -2.95 earnings per share for the current fiscal year.

Insider Activity at Alumis

In related news, Director Srinivas Akkaraju purchased 546,581 shares of the company’s stock in a transaction that occurred on Tuesday, September 8th. The stock was acquired at an average price of $10.63 per share, with a total value of $5,810,156.03. Following the completion of the purchase, the director directly owned 4,937,026 shares in the company, valued at $52,480,586.38. This trade represents a 12.45% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 99,754 shares of company stock valued at $1,037,804 in the last quarter. 33.70% of the stock is currently owned by company insiders.

Alumis is a clinical-stage biopharmaceutical company developing medicines for autoimmune and inflammatory diseases. The company uses data and computational tools to support the discovery and development of targeted treatments. Its lead investigational program, ESK-001, is an oral, selective TYK2 inhibitor being studied for conditions including plaque psoriasis and systemic lupus erythematosus. Alumis is also advancing other drug candidates for immune-mediated diseases. These medicines remain in clinical development and are not approved for commercial use.

Read More

Receive News & Ratings for Alumis Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alumis Inc and related companies with MarketBeat.com's FREE daily email newsletter.